|Bid||0.442 x 800|
|Ask||0.450 x 800|
|Day's Range||0.4348 - 0.4520|
|52 Week Range||0.2750 - 0.8600|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will also host one-on-one meetings through BIO CEO & Investor conference, which is one of the largest, unbiased forums of institutional investors, industry analysts, and biotechnology executives. Conference attendees can request meetings through the One-on-One Partnering platform, while non-attendees can send meeting requests to Joe Green at Edison Advisors.
EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on Wednesday, March 20th, 2019 to discuss EyeGate’s de novo application strategy for its Ocular Bandage Gel (OBG) product, which will cover the clinical plan, data to date, and potential submission timelines. EyeGate’s OBG platform, a unique cross-linked hyaluronic acid compound, has potentially broad applications in managing ocular surface damage due to a variety of conditions, ranging from punctate epitheliopathies (PE) commonly found in dry eye patients, to large epithelial defects like those that occur following photorefractive keratectomy (PRK). EyeGate’s OBG platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.
EyeGate (EYEG) announced Q3 financial results and provided a business update. To-date, EYEG has received $13.8M in upfront and milestones under the two agreements, including ~$300k in the most recent quarter. While the yoy decrease reflects a change in activity from the relatively large EGP-437 trials to the smaller OBG studies, the qoq increase is a result of continued progression of both OBG programs.
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Shares of EyeGate exploded on Tuesday on tremendous volume after reporting third quarter financial results. Shares of Viking Therapeutics were little changed ...
Eighty-three percent of healthcare organizations responding to an American Telemedicine Association* poll said they are highly likely to invest in telehealth with operational efficiency and convenience in mind. Of the 171 healthcare executives participating in the annual ATA Executive Leadership Survey, 88% of those who are likely to purchase telehealth tools are planning to do so. "This executive leadership survey confirms undeniably today's leaders view telemedicine as a major driver in transforming healthcare," said Jonathan Linkous, CEO, American Telemedicine Association.
EyeGate (EYEG) reported Q2 2018 financial results and provided a business update. Through Q2, EYEG collected $13.5M from Valeant related to upfront payments and development milestones associated with the development agreements for EGP-437 in anterior uveitis and post-cataract surgery. In terms of how these payments are recognized on EYEG’s financial statements, as a reminder an updated FASB standard governing revenue-recognition for contracts with customers resulted in a $9.5M adjustment to EYEG’s deferred revenue balance (as of Jan 1, 2018) – this is solely an accounting adjustment with no cash effect.
As we noted in our Q1 ’18 earnings update in late-May, Eyegate Pharmaceuticals' (EYEG) diligence in rapidly responding to FDAs follow-on questions related to their IDE submission has been key to keeping their Ocular Bandage Gel (OBG) programs on-track with updated forecasted timelines. EYEG had previously been guiding for commencement of both studies during Q3 (i.e.
On July 24, EyeGate Pharmaceuticals (EYEG) announced that it has secured FDA approval for two investigational device exemption applications related to pilot studies for the company’s OBG (ocular bandage gel) product scheduled to commence in the third quarter. In one pivotal study, the company will compare the OBG (or CHMA-S) product with the combination of bandage contact lens and artificial tears, which is the current standard of care for patients who have undergone photorefractive keratectom and require accelerated re-epithelialization of the corneal wounds.
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).